Future testing for The National Newborn Bloodspot Screening Laboratory (NNBSL) in Children's Health Ireland (CHI).

born bloodspot screening service. The future testing being reviewed is for a combined molecular screening of two disorders: Severe Combined Immunodeficiency (SCID) and Spinal Muscular Atrophy (SMA). The current expectation is that any proposal will need to cover the full equipment solution (analyser

s, reagents, consumables, auxiliary equipment) for SMA and SCID testing from sample receipt to result. The detailed scope will be issued with any potential formal procurement that may be initiated, but as a minimum will include the provisio